back to top

Long-acting HIV treatment may help patients in Pakistan unable to take daily pills, says US expert

Islamabad: A long-acting HIV treatment combination may help HIV-positive people in Pakistan who struggle to take daily medicines achieve and maintain viral suppression, a US infectious diseases expert says, as Pakistan faces a wide gap between the estimated number of people living with HIV and those receiving treatment.


Pakistan’s latest estimates put the number of people living with HIV at more than 417,000. About 92,000 are registered for care and roughly 68,000 receive antiretroviral treatment. A Ministry of Health reply to parliament recorded 3,900 children newly registered with HIV between January 2025 and June 2026, an average of about seven a day.


In a written interview with The News, Dr Monica Gandhi, professor of medicine at the University of California, San Francisco, said patients at the Ward 86 Clinic who began treatment with detectable HIV achieved viral suppression within 13 weeks of starting long-acting lenacapavir and cabotegravir. They remained suppressed, while patients who were already suppressed maintained that status during follow-up, which had a median duration of 100 weeks.


Dr. Gandhi responded to the questions with the study’s first author, Nathanael Gistand, an undergraduate student in Pharmaceutical Chemistry at the University of California, Davis. The clinic’s patients included people with extensive treatment histories, drug resistance and difficulty taking oral medicines. Many faced barriers such as substance use and housing insecurity.


The findings suggest long-acting treatment could help selected patients achieve and maintain viral suppression without taking oral therapy every day, Dr. Gandhi said. In Pakistan, where many people estimated to be living with HIV are not receiving treatment, this approach could potentially improve outcomes for patients who find daily medication difficult, if they can access injections and attend follow-up appointments.


Dr. Monica Gandhi said generic versions of lenacapavir and cabotegravir are expected by 2028 and urged pharmaceutical companies to improve access in low- and middle-income countries. Cabotegravir is not available through Pakistan’s ART centres, according to a recent study of providers and programme stakeholders.


The Drug Regulatory Authority of Pakistan (DRAP) registered lenacapavir in October as a twice-yearly injection for HIV prevention, clearing the way for local manufacture, although pricing approval could delay its availability. That registration is for prevention; the study examined lenacapavir with cabotegravir as treatment for people already living with HIV. The combination is not an approved treatment regimen.
Dr. Monica Gandhi said the combination could suit patients whose treatment histories or drug resistance make other long-acting regimens unsuitable. Rilpivirine, used with cabotegravir in the approved long-acting combination, cannot be used in people with previous resistance to NNRTI drugs. Lenacapavir may have a higher barrier to resistance, she said.


Injections still require reliable follow-up. Gandhi said clinicians need to check drug interactions, monitor viral loads and tolerability, and help patients receive doses on time. Delayed or missed injections can lead to viral rebound and drug resistance as medicine levels fall. Her clinic uses scheduling, reminders, outreach and coordinated follow-up to reduce those risks.


For people returning to care after dropping out, Gandhi said clinicians assess viral load and resistance to identify changes that may have developed during the interruption. Navigators and social workers can help address barriers to re-engagement. People who struggle with daily medicines because of mental health difficulties, substance use, unstable housing, stigma or lack of privacy may benefit from long-acting options, she said.


The US researcher also pointed to unsafe medical practices and needle reuse as causes of HIV infections among children in Pakistan. Safe procedures and universal precautions in healthcare settings are essential, she said, alongside better use of HIV treatment to prevent transmission from mothers to children.


Long-acting treatment may also become an option for younger patients. Gandhi cited encouraging findings among adolescents and safety and drug-level data from a study of children aged two to 12. Paediatric care requires parents’ involvement to support timely injections, clinical follow-up and transport to clinics, she said.


Researchers are also investigating possible approaches to an HIV cure, including combinations of broadly neutralising antibodies and vaccines. Gandhi said it was difficult to predict when a functional cure might be achieved, but some patients in investigational studies have remained suppressed for months after stopping treatment before the virus eventually returned.

Get in Touch

spot_imgspot_img

Related Articles

Get in Touch

1,500FansLike
2,000FollowersFollow
230FollowersFollow
500SubscribersSubscribe

Latest Posts